Cargando…
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas
Genome-wide molecular approaches have substantially elucidated molecular alterations and pathways involved in the oncogenesis of brain tumors. In gliomas, several molecular biomarkers including IDH mutation, 1p/19q co-deletion, and MGMT promotor methylation status have been introduced into neuropath...
Autores principales: | Haberler, Christine, Wöhrer, Adelheid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967248/ https://www.ncbi.nlm.nih.gov/pubmed/24559763 http://dx.doi.org/10.5414/NP300758 |
Ejemplares similares
-
Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma
por: Preusser, Matthias, et al.
Publicado: (2014) -
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
por: Bienkowski, Michal, et al.
Publicado: (2015) -
Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers
por: Berghoff, Anna S., et al.
Publicado: (2013) -
The Role of ATRX in Glioma Biology
por: Nandakumar, Pravanya, et al.
Publicado: (2017) -
Significance of TERT and ATRX mutations in glioma
por: Liu, Jiayu, et al.
Publicado: (2019)